Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

2(50%)

Results Posted

50%(1 trials)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Detailed Status

Completed2

Active, not recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

active_not_recruiting125%

completed250%

recruiting125%

Recent Activity

2 active trials

Showing 4 of 4

recruitingphase_2

Study of Lacutamab in Peripheral T-cell Lymphoma

NCT04984837

completedphase_2

Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer

NCT02143219

active_not_recruitingphase_2

Nordic Pancreatic Cancer Trial (NorPACT) - 1

NCT02919787

completedphase_2

1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

NCT00345696

Clinical Trials (4)

Showing 4 of 4 trials

NCT04984837Phase 2

Study of Lacutamab in Peripheral T-cell Lymphoma

Recruiting

NCT02143219Phase 2

Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer

Completed

NCT02919787Phase 2

Nordic Pancreatic Cancer Trial (NorPACT) - 1

Active Not Recruiting

NCT00345696Phase 2

1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4